- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
ProMIS Neurosciences Inc (PMN)
ProMIS Neurosciences Inc stock price live, this page displays NASDAQ PMN stock exchange data. View the PMN premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the ProMIS Neurosciences Inc real time stock price chart below.
What Is the ProMIS Neurosciences Inc Stock Price Today?
The ProMIS Neurosciences Inc stock price today is 3,290.
What Is the Stock Symbol for ProMIS Neurosciences Inc?
The stock symbol for ProMIS Neurosciences Inc is "PMN."
What Stock Exchange Does ProMIS Neurosciences Inc Trade On?
ProMIS Neurosciences Inc is listed and trades on the NASDAQ stock exchange.
Is ProMIS Neurosciences Inc a Good Stock to Buy?
Determining whether ProMIS Neurosciences Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PMN quote. (ISIN: CA74346M5054)
What Is the ProMIS Neurosciences Inc Stock Price Today?
The ProMIS Neurosciences Inc stock price today is 3,290.
What Is the Stock Symbol for ProMIS Neurosciences Inc?
The stock symbol for ProMIS Neurosciences Inc is "PMN."
What Stock Exchange Does ProMIS Neurosciences Inc Trade On?
ProMIS Neurosciences Inc is listed and trades on the NASDAQ stock exchange.
Is ProMIS Neurosciences Inc a Good Stock to Buy?
Determining whether ProMIS Neurosciences Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PMN quote. (ISIN: CA74346M5054)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.980
3.790
52 wk Range
2.780
27.400
PMN is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.9803.790
52 wk Range
2.78027.400
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
PMN Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
42.324
Upside
+1,186.44%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
RSI suggests the stock is in oversold territory
Form 8K PROMIS NEUROSCIENCES INC. For: 12 November- Investing.com
- Form 8K PROMIS NEUROSCIENCES INC. For: 12 November
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Analyst Ratings
7 Buy
0 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 42.324
(+1,186.44% Upside)
ProMIS Neurosciences Inc Earnings Call Summary for Q3/2026
- ProMIS Q3 2026 net loss narrowed to $8.2M ($0.89/share) vs. $11.6M ($5.93/share) YoY; cash position of $44.1M expected to fund ops through 2027.
- R&D spending fell 32% YoY to $6.7M as PRECISE-AD Alzheimer's trial nears completion; all patient visits expected to conclude in Q4 2026.
- Unblinded 12-month PRECISE-AD data due Q1 2027; interim results showed no ARIA-E cases and mild ARIA-H rates, supporting safety profile claims.
- Management planning End-of-Phase II FDA meeting post-readout and designing registration study; developing subcutaneous formulation of PMN310 in parallel.
- CEO Warma targets 15-20% slowing of decline as meaningful efficacy signal; stock down 49% YTD amid high volatility, trading at $3.48 in regular session.
Last Updated: 2026/11/13, 00:36
Read Full TranscriptEarnings
Latest Release
Aug 13, 2026
EPS / Forecast
-1,28 / -0,18
Revenue / Forecast
-- / --
Compare PMN to Peers and Sector
Metrics to compare | PMN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPMNPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.8x | −1.7x | −0.2x | |
PEG Ratio | −0.01 | −0.31 | 0.00 | |
Price/Book | 0.7x | 1.8x | 2.6x | |
Price / LTM Sales | - | 2.0x | 2.8x | |
Upside (Analyst Target) | - | 391.9% | 65.0% | |
Fair Value Upside | Unlock | 15.0% | 9.6% | Unlock |
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company’s proprietary discovery platform comprises ProMIS, which enables drug discovery through a combination of protein biology, physics, and supercomputing. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer's disease; PMN267 for the treatment of amyotrophic lateral sclerosis; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils for treating multiple system atrophy. The company also develops PNM440, an alpha-synuclein vaccine for treating multiple synucleinopathies; and PMN311, an amyloid-beta vaccine for the treatment of Alzheimer's. In addition, it is developing therapies for frontotemporal lobar degeneration, Huntington’s disease, progressive supranuclear palsy, corticobasal degeneration, and schizophrenia. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. is headquartered in Toronto, Canada.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the ProMIS Neurosciences (PMN) Stock Price Today?
The ProMIS Neurosciences stock price today is 3,290 USD.
What Stock Exchange Does ProMIS Neurosciences Trade On?
ProMIS Neurosciences is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for ProMIS Neurosciences?
The stock symbol for ProMIS Neurosciences is "PMN."
What Is the ProMIS Neurosciences Market Cap?
As of today, ProMIS Neurosciences market cap is 31,210M USD.
What Is ProMIS Neurosciences's Earnings Per Share (TTM)?
The ProMIS Neurosciences EPS (TTM) is -5,65.
From a Technical Analysis Perspective, Is PMN a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has ProMIS Neurosciences Stock Split?
ProMIS Neurosciences has split 2 times.
How Many Employees Does ProMIS Neurosciences Have?
ProMIS Neurosciences has 11 employees.
What is the current trading status of ProMIS Neurosciences (PMN)?
As of Nov 15, 2026, ProMIS Neurosciences (PMN) is trading at a price of 3,290 USD, with a previous close of 3,480 USD. The stock has fluctuated within a day range of 2,980 USD to 3,790 USD, while its 52-week range spans from 2,780 USD to 27,400 USD.
What Is ProMIS Neurosciences (PMN) Price Target According to Analysts?
The average 12-month price target for ProMIS Neurosciences is 42,324 USD, with a high estimate of 99.9194057 USD and a low estimate of 14.98773565 USD. 7 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +1 186,44% Upside potential.
What Is the PMN Premarket Price?
PMN's last pre-market stock price is 3,800 USD. The pre-market share volume is 4 480,000, and the stock has decreased by 0,320, or 9,200%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.